Abstract
Variants of adiponectin gene have been reported to be associated with coronary heart disease (CHD), but the available data on this relationship are inconsistent. A meta-analysis was performed to quantitatively analyse the association of adiponectin gene polymorphisms with coronary artery disease using previous case-control studies in Chinese Han populations. Several electronic databases were searched for relevant articles up to January 2011. After data collection and gene loci selection, a meta-analysis was performed to assess heterogeneity, combine results and evaluate variations. Publication bias was examined by the Egger's linear regression test. Hardy-Weinberg equilibrium (HWE) test and by omitting one study at a time was employed for the sensitivity analysis. Eleven studies covering 4303 subjects focusing on two polymorphisms [+45T→G (rs2241766) and +276G→T (rs1501299)] in the adiponectin gene and risk of CHD were included in the meta-analysis. Combined analyses of studies of the SNP+45 showed no significant overall association with CHD, yielding ORs of 1·03 (0·80, 1·34) and 1·32 (0·86, 2·03) under a dominant and recessive model, respectively, with strong evidence of heterogeneity. Similar results were also obtained in other genetic models. Concerning SNP+276, a significantly decreased CHD risk was observed under a dominant model, a codominant model and a allele contrast model, with an odds ratio of 0·67 (0·54, 0·83), 0·77 (0·62, 0·94) and 0·69 (0·55, 0·86), respectively. Sensitivity analysis confirmed the reliability and stability of this meta-analysis. The accumulated evidence suggested that the adiponectin gene polymorphism, SNP+45, is not associated with CHD, but the SNP+276T allele might be associated with decreased risk of CHD in the Chinese Han population. More well-designed large studies are required for the validation of this association.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.